Mode
Text Size
Log in / Sign up
N/A N=4,071 Randomized Double-blind Treatment

China Antihypertensive Trial in Acute Ischemic Stroke

Ischemic Stroke

Enrolled (actual)
4,071
Serious AEs
0.0%
Results posted
Nov 2014
Primary outcome: Primary: A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days. — 681; 683 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Active antihypertensive treatment (Other)
Age
Adult, Older Adult · 22+ yrs
Sex
All
Sponsor
Tulane University
Primary completion
May 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days.
681; 683
SECONDARY
A Combination of All-cause Mortality and Major Disability at the 3-month Post-treatment Follow-up.
502; 500
SECONDARY
Mortality
68; 54
SECONDARY
Recurrent Stroke
28; 43
SECONDARY
Other Vascular Events
59; 48
SECONDARY
Long-term Neurological and Functional Status
1.0; 1.0
SECONDARY
Cognitive Function (the Mini-Mental State Examination)
26; 26
SECONDARY
Cognitive Function (Montreal Cognitive Assessment)
22; 22
SECONDARY
Quality of Life

Summary

This randomized trial tests the effect of early blood pressure reduction on major disability and death among patients with acute ischemic stroke in china.

Eligibility Criteria

Inclusion Criteria

  • Age ≥22 years
  • Ischemic stroke onset within 48 hours confirmed by imaging (CT scan or MRI) study
  • Systolic BP≥140 and <220 mm Hg and diastolic BP≥80 mm Hg
  • No contraindications to antihypertensive treatment
  • Able and willing to sign informed consent by patients or their direct family members

Exclusion Criteria

  • Individuals with hemorrhagic stroke
  • Individuals with severe heart failure (NY Heart Association class III and IV), myocardial infarction, unstable angina, aortic dissection and cerebrovascular stenosis
  • Individuals in a deep coma
  • Individuals with resistant hypertension [systolic BP ≥170 mm Hg despite use of 4 or more antihypertensive medications for half a year or longer]
  • Intravenous thrombolytic therapy (such as intravenous rtPA)
  • Individuals who are unable to participate in follow-up examination
  • Current pregnant women
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01840072). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search